Migraine and Magnesium: What the Clinical Evidence Shows

Migraine and Magnesium: What the Trials Show — Proco evidence review
Migraine and Magnesium: What the Trials Show — Proco evidence review

Magnesium is one of the few supplements with a real guideline endorsement for migraine prevention — the American Academy of Neurology and American Headache Society class it as "probably effective," their second-highest evidence tier.1 That's a genuinely different footing than most things marketed for migraine. But the guideline is over a decade old, the underlying trials are small and they don't all agree, a later systematic review applying the same grading scheme scored the evidence a tier lower, and the doses that produced results — generally 360–600mg of elemental magnesium a day — sit above what a single serving of most magnesium supplements provides, including ours. This article walks through what the trials actually found, what the dose gap means in practice, and why magnesium is an option to discuss with a doctor, not a stand-in for prescribed migraine treatment.

Corrected September 2026: an earlier version of this article described "the two trials behind the guideline" and covered only the two that were positive. It omitted a third randomized trial — Pfaffenrath et al., 1996 — which found no benefit over placebo and was stopped early for that reason. It is now included below. We also mischaracterised the 2018 systematic review: it did not describe the evidence as "suggestive but not conclusive." Applying the same American Academy of Neurology scheme the 2012 guideline used, it graded magnesium Grade C, "possibly effective" — one tier lower than the guideline's Level B. That is corrected below too.

What the guideline actually says

In 2012, the Quality Standards Subcommittee of the American Academy of Neurology (AAN) and the American Headache Society (AHS) published an evidence-based guideline update on complementary treatments for episodic migraine prevention in adults.1 The panel reviewed 284 abstracts and ultimately assessed 49 Class I or Class II articles. Magnesium was rated Level B — "probably effective," the second tier in a four-level system (A = established effective, B = probably effective, C = possibly effective, U = evidence inadequate/conflicting). That puts magnesium in the same evidence class as several non-prescription options clinicians already discuss with migraine patients, alongside riboflavin and feverfew; butterbur was the only Level A entry. We cover two of those neighbours in riboflavin and CoQ10 for migraine, and why we don't sell them.

Three things worth being direct about. First, "probably effective" is not "proven" — it's a real classification, not marketing shorthand, and it reflects a genuinely limited evidence base: a handful of small randomized trials, not a large modern trial program. Second, this guideline update is now over a decade old and its literature search ran only to May 2009. Third, and most importantly, a 2018 systematic review that re-applied the AAN's own classification scheme to the magnesium trials landed on Grade C, "possibly effective" — a tier below the guideline — while still describing 600mg of magnesium dicitrate as a safe and cost-efficient option in clinical use.5 A more recent narrative review (2025) reaffirmed that magnesium is generally recommended as a preventive option, with dose-dependent gastrointestinal tolerability as its main downside rather than a safety signal beyond that.6 So the fair summary is not that magnesium's standing has been reaffirmed and left alone: it is that the guideline still says Level B, a later independent review of the same trials said Level C, and nobody has run the large modern trial that would settle it.

41.6%
The reduction in migraine attack frequency seen in the magnesium group of the largest positive placebo-controlled trial, versus 15.8% with placebo, over 12 weeks at 600mg elemental magnesium/day (p<0.05, n=81).2 A second randomized trial the same year, at a comparable dose, found nothing.7

The three randomized trials that matter — including the one that failed

Peikert et al., 1996 (Cephalalgia) — positive. The most-cited trial: 81 adults with migraine by International Headache Society criteria, mean attack frequency 3.6 per month, randomized to 600mg/day of magnesium (as trimagnesium dicitrate, 24 mmol elemental magnesium) or placebo for 12 weeks after a 4-week baseline period.2 In weeks 9–12, attack frequency dropped 41.6% in the magnesium group versus 15.8% with placebo (p<0.05), and the number of migraine days and the drug consumption for symptomatic treatment both fell significantly too. What the post-hoc reading often leaves out: the duration and intensity of attacks, and drug consumption per attack, only tended to improve and failed to reach significance. Adverse events were diarrhoea in 18.6% of participants and gastric irritation in 4.7%.

Pfaffenrath et al., 1996 (Cephalalgia) — negative. Published the same year, in the same journal, at a comparable dose: a multicentre, prospective, randomized, double-blind, placebo-controlled trial of 10 mmol of magnesium twice daily in adults with two to six migraine attacks a month without aura.7 A planned interim analysis at 69 patients (35 magnesium, 34 placebo) found the number of responders was 10 in each group — 28.6% on magnesium versus 29.4% on placebo — and, per the study protocol, that was a major reason to discontinue the trial. There was no benefit on the number of migraine days or migraine attacks either, and doctors' and patients' final assessments of efficacy were largely equivocal. Tolerability was worse than in Peikert: 45.7% of the magnesium group reported adverse events, mostly soft stool and diarrhoea, against 23.5% on placebo. Any honest account of this evidence base has to carry this trial. It is one of the two Class I trials in the literature, and it is the one that found nothing.

Facchinetti et al., 1991 (Headache) — positive, with caveats. A smaller, earlier double-blind trial in 20 women with menstrual migraine tested 360mg/day of magnesium (as magnesium pyrrolidone carboxylic acid), taken from day 15 of the cycle through the onset of menstruation, for two months.3 At the second month the Pain Total Index fell in both the placebo and magnesium groups, with the magnesium group showing the lowest values (P<0.03); the number of days with headache was reduced only in the magnesium group, and premenstrual distress scores improved too. Two important limits: the trial had 20 participants in total, and the following two months were open-label, with everyone receiving magnesium. It remains one of the earliest signals that magnesium might matter specifically around the hormonal drop that precedes a period — a pattern later work has continued to explore, and one we look at separately in PMS, PMDD and magnesium.

The 2018 systematic review found only five eligible randomized, double-blind, placebo-controlled trials out of 204 search results. One of two Class I trials showed a significant reduction in attacks; two of three Class III trials showed a significant reduction in the primary efficacy parameters.5 That's the honest state of the science: enough for a guideline body to call it probably effective in 2012, enough for an independent review to call it possibly effective in 2018, and not enough to call it proven the way a prescription preventive is.

One Class I trial found a 41.6% drop in attacks. The other Class I trial, at a comparable dose, was stopped early because the magnesium and placebo groups responded identically. Both are part of the evidence.

Who the trials suggest might benefit most

Across the trial evidence and the American Migraine Foundation's clinical summary, two subgroups come up repeatedly as the strongest candidates for a magnesium trial under a doctor's guidance: people with migraine with aura, and people with menstrual migraine tied to the drop in estrogen before a period.4 Intravenous magnesium sulfate — a different, clinician-administered intervention, not a supplement — has separately shown benefit for acute migraine with aura in emergency and clinic settings. That's a different use case from daily oral prevention and isn't what this article, or our product, addresses. If you're not certain which headache type you're dealing with in the first place, start with how to tell migraine, tension headache and cluster apart — the answer changes what's worth trying.

The dose gap: trials vs. a standard supplement serving

This is the part worth being upfront about. The trials behind the Level B rating used 360–600mg of elemental magnesium per day — meaningfully more than a single serving of most oral magnesium supplements, including ours — and they used different magnesium salts (trimagnesium dicitrate, magnesium pyrrolidone carboxylate, magnesium-aspartate-hydrochloride), not glycinate. We explain why we chose glycinate, and what the absorption evidence does and doesn't show for it, in our write-up on the form.

Key takeaway: One serving of Magnesium Glycinate (three capsules) provides 275mg of elemental magnesium — a fully disclosed, single-ingredient dose, but below the 360–600mg used in the migraine-prevention trials above, and in a different salt from any of them. It's not formulated or dosed to replicate those studies, and taking more than the labeled serving to try to close that gap isn't something to do without talking to a doctor first — especially since total daily magnesium from food, other supplements, and any medication needs to be considered together, and higher doses raise the odds of diarrhoea and GI upset. How much magnesium is too much goes through the upper-intake question.

None of this means the product "doesn't work" — it means the trial evidence and this specific product's labeled dose and salt aren't the same thing, and we'd rather say that plainly than let the guideline's Level B rating imply more than the label actually delivers. Magnesium Glycinate is sold for general sleep and nervous-system support, which is a different claim from migraine prevention. If migraine prevention is the specific goal, that dose gap is exactly the kind of detail worth bringing to a doctor or headache specialist, who can weigh it against your health history, current medications, and the dose actually used in the trials.

Safety, interactions, and why this isn't a solo decision

Magnesium is generally well tolerated, and diarrhoea is the most common side effect at higher doses — usually a sign to reduce the amount, not a safety emergency, though note it affected 45.7% of the magnesium group in the negative trial above.76 But magnesium supplements can interact with certain antibiotics, some blood pressure and heart medications, and diuretics, and people with kidney disease need medical guidance before supplementing at all, since impaired kidneys can't clear excess magnesium normally.4 Our interaction guide lists what to check. If you're currently on a prescribed migraine preventive (like a beta-blocker, anticonvulsant, or CGRP-targeted medication) or an acute treatment like a triptan, magnesium isn't something to add on your own to "stack" with what's prescribed — bring it up with the prescriber so they can check for interactions and decide whether it fits your treatment plan.

Bottom line

Magnesium has a real, guideline-recognized place in the migraine-prevention conversation — Level B, "probably effective" — but that rests on a five-trial literature in which one Class I trial found a 41.6% drop in attack frequency and the other, at a comparable dose, was halted early for finding no difference at all, and in which an independent 2018 review re-graded the evidence a tier lower. That's a legitimate, evidence-backed option some clinicians consider, not a cure and not proof it will work for any individual. Our Magnesium Glycinate delivers a fully disclosed 275mg elemental-magnesium serving — useful information for sleep and nervous-system support in its own right, as our complete magnesium guide sets out, but below the doses actually studied for migraine prevention and in a different salt. If migraine is what you're trying to address, the right first step is a conversation with a doctor or headache specialist about whether magnesium fits your situation, at what dose, and alongside what else.

This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.

References

  1. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78(17):1346–1353. pubmed.ncbi.nlm.nih.gov/22529203
  2. Peikert A, Wilimzig C, Köhne-Völland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–263. pubmed.ncbi.nlm.nih.gov/8792038
  3. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31(5):298–301. pubmed.ncbi.nlm.nih.gov/1860787
  4. American Migraine Foundation. Magnesium for Migraine. americanmigrainefoundation.org/resource-library/magnesium-migraine
  5. von Luckner A, Riederer F. Magnesium in Migraine Prophylaxis—Is There an Evidence-Based Rationale? A Systematic Review. Headache. 2018;58(2):199–209. doi:10.1111/head.13217. pubmed.ncbi.nlm.nih.gov/29131326
  6. Tepper SJ, Tepper K. Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur. Current Pain and Headache Reports. 2025;29(1):33. doi:10.1007/s11916-025-01358-3. link.springer.com/article/10.1007/s11916-025-01358-3
  7. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine — a double-blind, placebo-controlled study. Cephalalgia. 1996;16(6):436–440. pubmed.ncbi.nlm.nih.gov/8902254

Also worth reading: Magnesium and Menopause: What the Evidence Shows for Sleep and Mood, and our Magnesium Glycinate product page.

Want to know what's actually in what you take? Join the list — no spam, just it straight.